Integrated Multidimensional Analysis Is Required for Accurate Prognostic Biomarkers in Colorectal Cancer

Abstract

CRC cancer is one of the deadliest diseases in Western countries. In order to develop prognostic biomarkers for CRC (colorectal cancer) aggressiveness, we analyzed retrospectively 267 CRC patients via a novel, multidimensional biomarker platform. Using nanofluidic technology for qPCR analysis and quantitative fluorescent immunohistochemistry for protein analysis, we assessed 33 microRNAs, 124 mRNAs and 9 protein antigens. Analysis was conducted in each single dimension (microRNA, gene or protein) using both the multivariate Cox model and Kaplan-Meier method. Thereafter, we simplified the censored survival data into binary response data (aggressive vs. non aggressive cancer). Subsequently, we integrated the data into a diagnostic score using sliced inverse regression for sufficient dimension reduction. Accuracy was assessed using area under the receiver operating characteristic curve (AUC). Single dimension analysis led to the discovery of individual factors that were significant predictors of outcome. These included seven specific microRNAs, four genes, and one protein. When these factors were quantified individually as predictors of aggressive disease, the highest demonstrable area under the curve (AUC) was 0.68. By contrast, when all results from single dimensions were combined into integrated biomarkers, AUCs were dramatically increased with values approaching and even exceeding 0.9. Single dimension analysis generates statistically significant predictors, but their predictive strengths are suboptimal for clinical utility. A novel, multidimensional integrated approach overcomes these deficiencies. Newly derived integrated biomarkers have the potential to meaningfully guide the selection of therapeutic strategies for individual patients while elucidating molecular mechanisms driving disease progression.

RETRACTED ARTICLE: Serum levels of PTEN mRNA in colorectal cancer: a case-control study

“…Colorectal cancer (CRC) is one of the most frequent tumors with high malignancy all over the world, especially in developed countries [1][2][3]. Although the incidence of CRC in China is lower than that in Western countries, it is still a substantial burden in China for its increasing morbidity in recent years [4].…”

Systems Biology in Kidney Transplantation: The Application of Multi-Omics to a Complex Model

“…However, KT is a complex trait where the functional outcome is a result of a combination of multiple factors requiring a metadimensional approach for data integration. Fitting models that are based on known outcomes (concatenation‐based integration, model‐based‐integration, transformation‐based‐integration) or using unsupervised learning strategies (iClustering, Bayesian approach) have already been applied in other fields such as oncology and could be translated to KT . This integrative strategy has the potential to find biomarkers for conclusive, noninvasive diagnosis and pathological staging that will aid in testing new therapies.…”

“…This analysis reduced the sample size needed for the study and helped in the detection of gene disruption with increased frequency in comparison to one‐dimensional approaches. Also, the improved accuracy of prognostic biomarkers to determine the aggressiveness of colorectal cancer using an integrated multidimensional analysis compared with the individual components was demonstrated . Moreover, the revolution of integrative omics studies has been also applied in molecular classifications of complex cancers into subtypes and has paved the way for the formation of international consortia such as The Cancer Genome Atlas and International Cancer Genome Consortium, aiming to compile publicly available omics data, which would have a profound impact on translating basic research into precision medicine .…”

Lessons from CKD-Related Genetic Association Studies–Moving Forward

“…Contrasting with the nephrology field, cancer biologists have been able to obtain various tissue samples pertaining to clinical cases and unveil many of the molecular pathophysiology mechanisms underlying cancer diversity (81,82). This strategy has allowed the delineation of numerous disease subtypes, increased accuracy of prognostic models, and tailoring of clinical trials.…”